BPG is committed to discovery and dissemination of knowledge
Featured Articles
2/27/2026 9:05:03 AM | Browse: 84 | Download: 209
 |
Received |
|
2025-10-25 09:01 |
|
Peer-Review Started |
|
2025-10-25 09:01 |
|
First Decision by Editorial Office Director |
|
2025-11-24 12:55 |
|
Return for Revision |
|
2025-11-24 12:55 |
|
Revised |
|
2025-12-02 22:08 |
 |
Publication Fee Transferred |
|
|
|
Second Decision by Editor |
|
2026-01-04 02:39 |
|
Second Decision by Editor-in-Chief |
|
|
|
Final Decision by Editorial Office Director |
|
2026-01-04 07:25 |
|
Articles in Press |
|
2026-01-04 07:25 |
|
Edit the Manuscript by Language Editor |
|
|
|
Typeset the Manuscript |
|
2026-02-10 08:14 |
|
Publish the Manuscript Online |
|
2026-02-27 08:35 |
| ISSN |
1007-9327 (print) and 2219-2840 (online) |
| Open Access |
This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/ |
| Copyright |
© The Author(s) 2024. Published by Baishideng Publishing Group Inc. All rights reserved. |
| Article Reprints |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
|
| Permissions |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
|
| Publisher |
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA |
| Website |
http://www.wjgnet.com |
| Category |
Gastroenterology & Hepatology |
| Manuscript Type |
Editorial |
| Article Title |
Lessons from extended induction and practical evidence for improving tofacitinib therapy in ulcerative colitis
|
| Manuscript Source |
Invited Manuscript |
| All Author List |
Yasser Fouad and Ahmed S Aboelela |
| Funding Agency and Grant Number |
|
| Corresponding Author |
Yasser Fouad, Department of Gastroenterology and Endemic Medicine, Faculty of Medicine, Minia University, El Horryia Street, Minia 19111, Egypt. yasserfouad10@yahoo.com |
| Key Words |
Tofacitinib; Ulcerative colitis; Induction therapy; Maintenance therapy; Janus kinase |
| Core Tip |
Partial or delayed responders with ulcerative colitis can be saved by extending tofacitinib induction from 8 weeks to 16 weeks without raising safety concerns. Evidence from the real world shows that this approach, especially in patients with biologic experience, results in higher remission rates and long-lasting drug persistence. Instead of a strict 8-week limit, a structured, response-guided algorithm enables clinicians to address modifiable risk factors like smoking, maximize long-term outcomes, and customize therapy. Now, extended induction ought to be seen as a logical, scientifically supported part of customized tofacitinib treatment. |
| Publish Date |
2026-02-27 08:35 |
| Citation |
Fouad Y, Aboelela AS. Lessons from extended induction and practical evidence for improving tofacitinib therapy in ulcerative colitis. World J Gastroenterol 2026; 32(9): 115785 |
| URL |
https://www.wjgnet.com/1007-9327/full/v32/i9/115785.htm |
| DOI |
https://dx.doi.org/10.3748/wjg.v32.i9.115785 |
All content on this site: Copyright © 1993-2026 Baishideng Publishing Group Inc, its licensors, and contributors. All rights are reserved, including those for text and data mining, AI training, and similar technologies. For all open access content, the relevant licensing terms apply.
